https://www.selleckchem.com/products/jke-1674.html
possible to arrive at valid, reliable, and reproducible parameters able to serve as references in the framework of follow-up of patients treated for cancer of the oral cavity or the oropharynx. No risk-stratification strategies exist for patients with recurrent oropharyngeal cancer (OPC). Retrospective analysis using data from prospective NRG Oncology clinical trials RTOG 0129 and 0522. Eligibility criteria included known p16 status and smoking history, and locoregional/distant recurrence. Overall survival (OS) was measured from date o
Gefällt mir
Kommentar
Teilen
